← Back to Search

Cell Therapy

Islet Transplantation for Type 1 Diabetes

Phase 1
Waitlist Available
Led By Fouad Kandeel, MD
Research Sponsored by City of Hope Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
No evidence of liver disease
Difficult to control Type 1 diabetes mellitus with documentation of negative basal and stimulated C-peptide and diagnosis of diabetes for at least 5 years
Must not have
Presence of a chronic disease that must be chronically treated with specific medications
Significant cardiovascular disease
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group

Summary

This trial will study whether islet cell transplantation can help people with type 1 diabetes who have trouble controlling their blood sugar, despite using standard insulin therapy and monitoring their blood sugar levels often.

Who is the study for?
This trial is for adults aged 18-65 with difficult to control Type 1 diabetes, experiencing severe blood sugar fluctuations despite using insulin and monitoring. Candidates must have had diabetes for at least 5 years, no chronic kidney or liver disease, and be able to follow a strict post-transplant regimen. Exclusions include significant heart disease, certain immune responses (high antibody levels), obesity (BMI over 30), active infections, substance abuse, psychiatric issues affecting treatment adherence, and any history of cancer except specific skin or cervical cancers.
What is being tested?
The study tests the safety and effectiveness of islet cell transplantation without steroids in managing Type 1 diabetes that's hard to control with standard treatments. It involves transplanting cells into patients who then receive an immunosuppressive drug regimen to prevent rejection of the new cells while avoiding glucocorticoids which can affect blood sugar levels.
What are the potential side effects?
Potential side effects may include low blood sugar episodes immediately after transplant due to insulin-producing cell adjustment; risks associated with immunosuppression such as increased infection susceptibility; possible organ inflammation from immune response; surgical complications like bleeding or infection at the transplant site.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My liver is healthy.
Select...
I have had Type 1 diabetes for over 5 years and it's hard to control.
Select...
I check my blood sugar at least four times a day and keep detailed records.
Select...
I often have low blood sugar episodes that I can't feel or that need help.
Select...
I am between 18 and 65 years old.
Select...
My kidneys are functioning well without significant protein loss.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I am on long-term medication for a chronic illness.
Select...
I have a serious heart condition.
Select...
I am not pregnant, breastfeeding, and I am willing to use effective contraception.
Select...
I am at a higher risk of bleeding or I am on long-term blood thinners.
Select...
I do not have an untreated mental health condition that could affect a transplant.
Select...
My cholesterol levels are high despite treatment.
Select...
I have anemia or another blood disorder that needs treatment.
Select...
I have a serious liver condition.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: 1Experimental Treatment2 Interventions
Islet cell transplantation alone
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Islet cell transplantation
2005
Completed Phase 1
~10

Find a Location

Who is running the clinical trial?

City of Hope Medical CenterLead Sponsor
602 Previous Clinical Trials
1,923,563 Total Patients Enrolled
2 Trials studying Diabetes
191 Patients Enrolled for Diabetes
National Institutes of Health (NIH)NIH
2,811 Previous Clinical Trials
8,161,221 Total Patients Enrolled
25 Trials studying Diabetes
64,177 Patients Enrolled for Diabetes
Fouad Kandeel, MDPrincipal InvestigatorCity of Hope Medical Center
1 Previous Clinical Trials
3 Total Patients Enrolled

Media Library

Islet cell transplantation (Cell Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT00706420 — Phase 1
Diabetes Research Study Groups: 1
Diabetes Clinical Trial 2023: Islet cell transplantation Highlights & Side Effects. Trial Name: NCT00706420 — Phase 1
Islet cell transplantation (Cell Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00706420 — Phase 1
~0 spots leftby Nov 2024